TY - JOUR
T1 - Transdermal deferoxamine prevents pressure-induced diabetic ulcers
AU - Duscher, Dominik
AU - Neofytou, Evgenios
AU - Wong, Victor W.
AU - Maan, Zeshaan N.
AU - Rennert, Robert C.
AU - Inayathullah, Mohammed
AU - Januszyk, Michael
AU - Rodrigues, Melanie
AU - Malkovskiy, Andrey V.
AU - Whitmore, Arnetha J.
AU - Walmsley, Graham G.
AU - Galvez, Michael G.
AU - Whittam, Alexander J.
AU - Brownlee, Michael
AU - Rajadas, Jayakumar
AU - Gurtner, Geoffrey C.
N1 - Publisher Copyright:
© 2015, National Academy of Sciences. All rights reserved.
PY - 2015/1/6
Y1 - 2015/1/6
N2 - There is a high mortality in patients with diabetes and severe pressure ulcers. For example, chronic pressure sores of the heels often lead to limb loss in diabetic patients. A major factor underlying this is reduced neovascularization caused by impaired activity of the transcription factor hypoxia inducible factor-1 alpha (HIF-1α). In diabetes, HIF-1α function is compromised by a high glucose-induced and reactive oxygen species-mediated modification of its coactivator p300, leading to impaired HIF-1α transactivation. We examined whether local enhancement of HIF-1α activity would improve diabetic wound healing and minimize the severity of diabetic ulcers. To improve HIF-1α activity we designed a transdermal drug delivery system (TDDS) containing the FDA-approved small molecule deferoxamine (DFO), an iron chelator that increases HIF-1α transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress. Applying this TDDS to a pressure-induced ulcer model in diabetic mice, we found that transdermal delivery of DFO significantly improved wound healing. Unexpectedly, prophylactic application of this transdermal delivery system also prevented diabetic ulcer formation. DFO-treated wounds demonstrated increased collagen density, improved neovascularization, and reduction of free radical formation, leading to decreased cell death. These findings suggest that transdermal delivery of DFO provides a targeted means to both prevent ulcer formation and accelerate diabetic wound healing with the potential for rapid clinical translation.
AB - There is a high mortality in patients with diabetes and severe pressure ulcers. For example, chronic pressure sores of the heels often lead to limb loss in diabetic patients. A major factor underlying this is reduced neovascularization caused by impaired activity of the transcription factor hypoxia inducible factor-1 alpha (HIF-1α). In diabetes, HIF-1α function is compromised by a high glucose-induced and reactive oxygen species-mediated modification of its coactivator p300, leading to impaired HIF-1α transactivation. We examined whether local enhancement of HIF-1α activity would improve diabetic wound healing and minimize the severity of diabetic ulcers. To improve HIF-1α activity we designed a transdermal drug delivery system (TDDS) containing the FDA-approved small molecule deferoxamine (DFO), an iron chelator that increases HIF-1α transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress. Applying this TDDS to a pressure-induced ulcer model in diabetic mice, we found that transdermal delivery of DFO significantly improved wound healing. Unexpectedly, prophylactic application of this transdermal delivery system also prevented diabetic ulcer formation. DFO-treated wounds demonstrated increased collagen density, improved neovascularization, and reduction of free radical formation, leading to decreased cell death. These findings suggest that transdermal delivery of DFO provides a targeted means to both prevent ulcer formation and accelerate diabetic wound healing with the potential for rapid clinical translation.
KW - Angiogenesis
KW - Diabetes
KW - Drug delivery
KW - Small molecule
KW - Wound healing
UR - http://www.scopus.com/inward/record.url?scp=84920416403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920416403&partnerID=8YFLogxK
U2 - 10.1073/pnas.1413445112
DO - 10.1073/pnas.1413445112
M3 - Article
C2 - 25535360
AN - SCOPUS:84920416403
SN - 0027-8424
VL - 112
SP - 94
EP - 99
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 1
ER -